EUCTR2020-001165-36-IT进行中（未招募）1 期
A Phase 2, Monocentric, Pilot Study to evaluate safety and efficacy of CC 486 (Oral Azacitidine) Plus Best Supportive Care as maintenance of response to sc azacitidine in IPSS higher risk elderly MDS patients - FLORENCE_CC-486_HRMDS
Dipartimento di Medicina Sperimentale e Clinica- Università di Firenze0 个研究点目标入组 10 人开始时间: 2021年2月10日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must satisfy the following criteria to be enrolled in the study:
- •1. Male or female subjects = 65 years of age at the time of signing the ICD;
- •2. Diagnosed, histologically confirmed at inclusion,
- •- Int-2 or High according to IPSS, or
- •- Very High, High or Intermediate according to IPSS-R, or
- •- Hypoplastic AML (20-30% BM blasts, previosuly considered MDS RAEB-T)
- •- myelodysplastic CMML (included in IPSS scoring, WBC < 13.x 109/L);
- •3. Should have undergone therapy with subcutaneous azacitidine for at least 4-6 cycles
- •( + 2 cycles)
- •4. Must have achieved CR/CRi, PR or SD with HI status, as evidenced by IWG Criteria 2006 ( APPENDIX E):
- •5. ECOG performance status of 0, 1, 2 (Appendix C);
- •6. Adequate bone marrow function based on ANCs = 1.0 x 109/L and platelet counts = 70 x 109/L.
- •7. Adequate organ function, defined as:
- •Serum bilirubin =1.5 times the upper limit of normal (ULN);
- •Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 times the ULN;
- •Serum creatinine = 2.5 times the ULN;
- •8.Male subjects with a female partner of childbearing potential must agree to practice abstinence or to the use of a physician-approved contraceptive method throughout the course of the study and avoid fathering a child during the course of the study and for 3 months following the last dose of azacitidine;
- •10. Understand and voluntarily sign an ICD prior to any study related assessments/procedures are conducted;
- •11. Able to adhere to the study visit schedule and other protocol requirements;
- •12. Ability to swallow study medication.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- Absence of confirmed hematological response ( IWG HI/PR/CR) after at least 4 to 6 months of azacitidine sc and maintenance of response for 2 additional cycles.
- •- Inability to provide a valid informed consent.
- •- Eligibility for HSCT
- •- Active infection
- •- Serum creatinine > 2 x ULN at screening.
- •- ECOG performance status > 2
- •- Left ventricular ejection fraction < 50% by echocardiography
- •- A history of repeated hospitalization for severe infections Systemic diseases that would prevent study treatment (e.g. uncontrolled hypertension, cardiovascular, renal, hepatic, metabolic, etc.)
- •- Clinical or laboratory evidence of chronic Hepatitis B or Hepatitis C (definition of chronic hepatitis follows EASL 2017 criteria).
- •- History of HIV positive test result (ELISA or Western blot).
- •- ALT or AST over 3 times superior to ULN at screening.
- •- Total bilirubin over 1.5 times superior to ULN at screening (patients with Gilbert syndrome are allowed to enter the study)
- •- Patients participating in another clinical trial other than an observational registry study.
- •- Patients with a history of another malignancy within the past 3 years, with the exception of basal skin carcinoma or cervical carcinoma in situ or completely resected colonic polyps carcinoma in situ.
- •- History of non-compliance to medical regimens, or patients who are considered potentially unreliable and/or not cooperative.
- •- Presence of a surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of study drug.
- •- History of drug or alcohol abuse within the 12 months prior to enrollment.
研究者
相似试验
已完成
2 期
AURA2on Small Cell Lung CancerJPRN-jRCT2080222500AstraZeneca KK46
进行中（未招募）
1 期
A randomized phase II pilot study to evaluate safety and efficacy of the addition of vismodegib to standard neoadjuvant chemotherapy in triple negative breast cancer patients.MedDRA version: 17.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006199Term: Breast cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancerEUCTR2014-001287-35-ESClínica Universidad de Navarra/Universidad de Navarra40
进行中（未招募）
不适用
Phase IIb pilot study for the evaluation of the safety and the feasibility of treatment simplification to tenofovir+emtricitabina+raltegravir or to lamivudine+abacavir+raltegravir in patients with optimal virological control and toxicity to the current combined antiretroviral regimen. - NDEUCTR2009-014316-35-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
已完成
1 期
Safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and effects of intravenous (IV) and intramuscular (IM) dosing of SPL028 (deuterated DMT fumarate [a serotonergic psychedelic]) in healthy volunteers and participants with major depressive disorder (MDD)Healthy participantsISRCTN42293056Cybin UK Ltd38
进行中（未招募）
不适用
/ASubjects affected by non-segmental vitiligoMedDRA version: 14.1Level: PTClassification code 10062080Term: Pigmentation disorderSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2011-000169-10-ITCLINUVEL PHARMACUETICALS LTD.60